<DOC>
	<DOCNO>NCT02096211</DOCNO>
	<brief_summary>This study intend gather short ( Pre-operative 4-years ) mid-term ( 5-years ) information regard performance safety commercially available 36mm CERAMAXÂ® Ceramic Ceramic Total Hip System cohort new study subject previously involve IDE study device .</brief_summary>
	<brief_title>Ceramic-on-Ceramic ( COC ) 36mm Acetabular Bearing Insert Post Approval Study-New Subjects ( COC36mmPAS )</brief_title>
	<detailed_description>Up 10 ( 5 original IDE + 5 new site ) A prospective , non-controlled , non-randomized , multicenter study . Subjects see clinic visit pre-operatively time consent , ( -90 day surgery ) post-operatively 6 week ( 1-92 day ) , 1 year ( 275-455 day ) , 2 year ( 640-820 day ) 3 year ( 1005-1185days ) , 4 year ( 1370-1550 day ) , minimum 5 year ( 1825- 2919 day ) . Data collect include : Pre-operatively subject history demographic ; Operative device detail ; Post-operatively Harris HIp score , Subject Hip Outcomes , Adverse Events . In order optimize mid-term follow-up compliance , site personnel permit contact study subject 3 4 year interval phone ( place clinic visit ) ass current status hip .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<criteria>Males females 21 75 time surgery . Individuals , opinion investigator , suitable candidate primary total hip replacement use device specify protocol . Individuals noninflammatory degenerative joint disease ( NIDJD ) composite diagnosis osteoarthritis , avascular necrosis , posttraumatic arthritis . Individuals willing able provide inform patient consent participation study ; Individuals willing able return followup specify study protocol ; Individuals willing able complete Subject Hip Outcomes questionnaire specify study protocol . Skeletally immature patient ( tibial femoral epiphysis close ) Evidence active infection may spread area body ( e.g. , osteomyelitis , pyogenic infection hip joint , overt infection , urinary tract infection , etc . ) The presence know neoplastic ( tumorcausing ) metastatic ( spread cancerous cell ) disease Significant neurologic musculoskeletal disorder disease may adversely affect gait , weight bear postoperative recovery ( e.g. , muscular dystrophy , multiple sclerosis ) Presence highly communicable disease ( ) may limit followup ( e.g. , immunocompromised condition , hepatitis , active tuberculosis , etc . ) Any condition may interfere postoperative recovery ( e.g. , Paget 's disease , Charcot 's disease ) Inadequate bone stock support device ( e.g. , severe osteopenia orosteoporosis ) Poor skin coverage around hip joint Use patient know allergy implant material Marked atrophy ( muscle and/or tissue loss ) deformity upper femur birth defect affect leg bone . Inflammatory degenerative joint disease ( like rheumatoid arthritis ) Subject participate IDE/IND clinical investigation , COC28/COC36 IDE PAS contralateral hip , investigational product last three month . Subject currently involve personal injury litigation , medicallegal worker 's compensation claim . Subject know drug alcohol abuser psychological disorder could affect ability comply protocol procedure and/or subjectcompleted questionnaire . The Subject woman pregnant lactating . The Subject medical condition le 2 year life expectancy .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Total hip replacement</keyword>
	<keyword>Total hip arthroplasty</keyword>
	<keyword>Hip joint replacement</keyword>
	<keyword>Hip prosthesis replacement</keyword>
</DOC>